Robert W. Baird Issues Positive Forecast for Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price

Jazz Pharmaceuticals (NASDAQ:JAZZ) had its price objective boosted by Robert W. Baird from $154.00 to $162.00 in a research note issued to investors on Monday,Benzinga reports. Robert W. Baird currently has an outperform rating on the specialty pharmaceutical company’s stock.

A number of other equities research analysts also recently weighed in on JAZZ. TD Cowen dropped their target price on Jazz Pharmaceuticals from $200.00 to $195.00 and set a “buy” rating for the company in a research report on Thursday, November 7th. Needham & Company LLC restated a “buy” rating and set a $207.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, November 7th. HC Wainwright restated a “buy” rating and set a $200.00 target price on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Royal Bank of Canada boosted their target price on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 23rd. Finally, StockNews.com upgraded Jazz Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Three analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average price target of $175.53.

Jazz Pharmaceuticals Trading Down 3.3 %

Shares of JAZZ opened at $117.59 on Monday. The stock has a fifty day moving average price of $112.22 and a two-hundred day moving average price of $110.35. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals has a 52-week low of $99.06 and a 52-week high of $134.17. The company has a market cap of $7.11 billion, a price-to-earnings ratio of 16.56, a PEG ratio of 1.02 and a beta of 0.57.

Insider Activity at Jazz Pharmaceuticals

In other news, SVP Mary Elizabeth Henderson sold 1,410 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $108.30, for a total value of $152,703.00. Following the completion of the sale, the senior vice president now directly owns 14,531 shares of the company’s stock, valued at $1,573,707.30. This trade represents a 8.85 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $110.84, for a total value of $110,840.00. Following the completion of the sale, the chief executive officer now directly owns 428,976 shares of the company’s stock, valued at approximately $47,547,699.84. The trade was a 0.23 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 6,110 shares of company stock valued at $720,160. Insiders own 4.20% of the company’s stock.

Hedge Funds Weigh In On Jazz Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the stock. CWA Asset Management Group LLC bought a new position in shares of Jazz Pharmaceuticals in the 3rd quarter valued at $3,197,000. Swedbank AB bought a new position in shares of Jazz Pharmaceuticals in the 2nd quarter valued at $106,936,000. Vanguard Group Inc. increased its stake in shares of Jazz Pharmaceuticals by 1.3% in the 1st quarter. Vanguard Group Inc. now owns 6,448,689 shares of the specialty pharmaceutical company’s stock valued at $776,551,000 after purchasing an additional 84,941 shares during the last quarter. Mitsubishi UFJ Trust & Banking Corp increased its stake in shares of Jazz Pharmaceuticals by 131.9% in the 1st quarter. Mitsubishi UFJ Trust & Banking Corp now owns 73,757 shares of the specialty pharmaceutical company’s stock valued at $8,818,000 after purchasing an additional 41,950 shares during the last quarter. Finally, Advisors Asset Management Inc. increased its stake in shares of Jazz Pharmaceuticals by 9.2% in the 1st quarter. Advisors Asset Management Inc. now owns 9,722 shares of the specialty pharmaceutical company’s stock valued at $1,171,000 after purchasing an additional 819 shares during the last quarter. Institutional investors own 89.14% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.